Vectibix Drug Interactions

Data from an interaction study involving Panitumumab (Vectibix) and irinotecan in patients with mCRC indicate that the pharmacokinetics of irinotecan and its active metabolite, SN-38, are not altered when the medicinal products are co-administered. Results from a cross-study comparison indicated that irinotecan-containing regimens (IFL or FOLFIRI) have no effect on the pharmacokinetics of panitumumab.
Panitumumab (Vectibix) should not be administered in combination with IFL chemotherapy or with bevacizumab-containing chemotherapy. A high incidence of severe diarrhoea was observed when panitumumab was administered in combination with IFL (see Precautions), and increased toxicity and deaths were seen when panitumumab was combined with bevacizumab and chemotherapy (see Precautions and Pharmacology: Pharmacodynamics under Actions).
The combination of Panitumumab (Vectibix) with oxaliplatin-containing chemotherapy is contraindicated for patients with mutant RAS mCRC or for whom RAS mCRC status is unknown. A shortened progression-free survival and overall survival time were observed in a clinical study in patients with mutant RAS tumours who received panitumumab and FOLFOX (see Precautions and Pharmacology: Pharmacokinetics under Actions).